Abbott and Alere: The Wedding Is Back On!
It seems so long ago. Back in February 2016, Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced their $5.8 billion deal. Abbott’s board okay’ed paying $56 per common share of Alere, representing a 51% premium to the company’s close on January 28, 2016. Abbott also assumed $2.6 billion of debt. The combination was expected to create a premier point-of-care testing business and to strengthen Abbott’s diagnostics presence. Alere’s main business is its point-of-care diagnostics and services, which are focused on the areas of infectious disease, cardio-metabolic disease, and toxicology. Point of care testing is a $5.5 billion segment, and one... Read More »DaVita Divests Seven Dialysis Clinics
DaVita Inc. (NYSE: DVA) isn’t usually on the sell-side of dialysis deals. In fact, the company hasn’t announced a sale from its renal care division in the past five years. But in late March, the Federal Trade Commission ordered DaVita to divest its ownership in seven dialysis clinics. That order was part of a settlement resolving charges that DaVita’s $358 million acquisition of Renal Ventures Management, LLC would be anticompetitive. At the time of that deal’s announcement in August 2015, Renal Ventures operated 36 dialysis clinics in six states. The company’s two divisions, Multispecialty Physician Partners and Physician Venture Partners, operated infusion... Read More »Sartorius AG Scores Two More Deals
Sartorius AG (FWB: SRT), a German pharmaceutical and laboratory equipment provider, has expanded with the acquisition of a medical device company and a digital health company for a combined total of $392.5 million. Sartorius operates through two divisions: bioprocess solutions and lab products & services. On March 3, 2017, Sartorius acquired privately-held Essen BioScience Inc. from SFW Capital Partners for $320 million. Essen develops and manufactures instruments, software, reagents and consumables which enable researchers to remotely image and quantify a wide variety of cellular processes over time. Through this acquisition, Sartorius significantly expands its portfolio for... Read More »Laboratories, MRI & Dialysis Deals Dropped in 2016
Deal volume settled down in 2016, following a very busy 2015 in the Laboratories, MRI & Dialysis sector. The 41 deals recorded represent a 21% decline compared with the 52 announced in 2015. Laboratories have had to adapt as hospitals and health systems have merged or closed in recent years. Some labs have evolved to offer coordinated diagnostics: offering tests that give on-the-spot diagnoses, handling bills and lab data from several sources and providers as an aid to accountable care organizations, and focusing on the patient experience to ensure repeat business. At the same time, deal value surged in 2016, up 166% year-over-year to $11.6 billion. Two multi-billion-dollar deals... Read More »
Strategic vs. Financial Healthcare Buyers in 2016
Every spring, we publish myraid statistics on the healthcare services deals announced the year before, in the form of The Health Care Services Acquisition Report. This year’s 23rd edition, which will available in late March, has this examination of what financial buyers targeted in 2016. Strategic buyers continued to dominate the health care services M&A market in 2016, as they have in the past. Their 683 deals made up 73% of the year’s deal volume. The $45.7 billion spent accounted for 63% of the combined total of $72 billion. A total of 259 deals, or 27% of the services deal volume in 2016, were carried out by financial buyers, such as private equity firms and real estate... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
